ERBB2 and breast carcinoma: This is especially problematic for breast cancer patients with tumors that lack expression of Her2/neu, progesterone receptor, and the estrogen receptor, denoted as triple-negative, and have few therapeutic options available (Hudis and Gianni, 2011).